Evidence map›Paper›PMID 33679760›Full record

ArticleFrontiers in immunology2021

Cyclic-di-GMP Induces STING-Dependent ILC2 to ILC1 Shift During Innate Type 2 Lung Inflammation.

Kellen J Cavagnero, Jana H Badrani, Luay H Naji, Michael B Amadeo, Anthea S Leng, Lee Diego Lacasa, Allyssa N Strohm, Samantha R Renusch, Suzanna S Gasparian, Taylor A Doherty

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Kellen J CavagneroDepartment of Medicine, University of California, San Diego, La Jolla, CA, United States.
Jana H BadraniDepartment of Medicine, University of California, San Diego, La Jolla, CA, United States.
Luay H NajiDepartment of Medicine, University of California, San Diego, La Jolla, CA, United States.
Michael B AmadeoDepartment of Medicine, University of California, San Diego, La Jolla, CA, United States.
Anthea S LengDepartment of Medicine, University of California, San Diego, La Jolla, CA, United States.
Lee Diego LacasaDepartment of Medicine, University of California, San Diego, La Jolla, CA, United States.
Allyssa N StrohmDepartment of Medicine, University of California, San Diego, La Jolla, CA, United States.
Samantha R RenuschDepartment of Medicine, University of California, San Diego, La Jolla, CA, United States.
Suzanna S GasparianDepartment of Medicine, University of California, San Diego, La Jolla, CA, United States.
Taylor A DohertyDepartment of Medicine, University of California, San Diego, La Jolla, CA, United States.
University of California, San Diego · US

Funding

TRM and airway inflammation and remodelingU19AI070535 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROIDE, DAVID H · 2006 to 2025
$34.2M
Training Grant in GastroenterologyT32DK007202 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA · 1985 to 2022
$7.7M
RBM3 regulation of type 2 innate lymphoid cells in allergic inflammationR01AI114585 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DOHERTY, TAYLOR A · 2015 to 2019
$2.3M
Targeting pathogenic innate lymphoid cells in airway diseaseI01BX005073 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI TAYLOR A DOHERTY · 2021 to 2026
–
BLRD VA I01 BX005073NIAID NIH HHS R01 AI114585NIAID NIH HHS U19 AI070535NIDDK NIH HHS T32 DK007202
6 · The paper itself

Abstract

Type 2 inflammation is found in most forms of asthma, which may co-exist with recurrent viral infections, bacterial colonization, and host cell death. These processes drive the accumulation of intracellular cyclic-di-nucleotides such as cyclic-di-GMP (CDG). Group 2 innate lymphoid cells (ILC2s) are critical drivers of type 2 lung inflammation during fungal allergen exposure in mice; however, it is unclear how CDG regulates lung ILC responses during lung inflammation. Here, we show that intranasal CDG induced early airway type 1 interferon (IFN) production and dramatically suppressed CD127+ST2+ ILC2s and type 2 lung inflammation during

Indexed as

Immunity, InnateAlternariaAlternariosisAnimalsCyclic GMPCytokinesInflammationLungMembrane ProteinsMiceMice, KnockoutPneumoniaSignal TransductionSTING Proteinbis(3',5')-cyclic diguanylic acidCyclic GMPCytokinesMembrane ProteinsSting1 protein, mouseSTING ProteinasthmaCOVID-19Cyclic-di-GMPILCILC1ILC2innate lymphoid cellSTING

Identifiers

PMID33679760
PMCPMC7935536
OpenAlexW3131673180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.